Table 1.
Characteristics of study subjects according to types of skin cancer
| Characteristic | NMSC |
Melanoma |
||||
|---|---|---|---|---|---|---|
| HCTZ users (n=1,327,256) | Non-HCTZ users (n=1,851,362) | p value | HCTZ users (n=1,327,673) | Non-HCTZ users (n=1,851,362) | p value | |
| Age, yr | 55.8 ± 12.7 | 55.1 ± 12.9 | < 0.001a | 55.8 ± 12.7 | 55.1 ± 12.9 | < 0.001a |
| Age_groups, yr | ||||||
| 18–34 | 44,664 (3.4) | 85,918 (4.6) | 44,664 (3.4) | 85,918 (4.6) | ||
| 35–49 | 393,682 (29.7) | 539,033 (29.1) | 393,707 (29.7) | 539,033 (29.1) | ||
| 50–64 | 552,018 (41.6) | 800,226 (43.2) | 552,092 (41.6) | 800,226 (43.2) | ||
| ≥ 65 | 336,892 (25.4) | 426,185 (23.0) | 337,210 (25.4) | 426,185 (23.0) | ||
| Sex | < 0.001a | < 0.001a | ||||
| Male | 693,107 (52.2) | 1,089,555 (58.9) | 693,265(52.2) | 1,089,555 (58.9) | ||
| Female | 634,149 (47.8) | 761,807 (41.1) | 634,408 (47.8) | 761,807 (41.1) | ||
| Charlson comorbidity index score | ||||||
| 0 (low) | 70,990 (5.3) | 118,303 (6.4) | 70,991 (5.3) | 118,303 (6.4) | ||
| 1–2 (medium) | 401,867 (30.3) | 628,634 (34.0) | 401,866 (30.3) | 628,634 (34.0) | ||
| ≥ 3 (high) | 854,399 (64.4) | 1,104,425 (59.7) | 854,816 (64.4) | 1,104,425 (59.7) | ||
| Concurrent use of photosensitizing drugsb | ||||||
| Amlodipine | 763,125 (57.5) | 1,062,828 (57.4) | 0.116 | 763,508 (57.5) | 1,063,077 (57.4) | 0.127 |
| Losartan | 620,168 (46.7) | 383,786 (20.7) | < 0.001a | 620,399 (46.7) | 383,869 (20.7) | < 0.001a |
| Valsartan | 417,282 (31.4) | 389,835 (21.1) | < 0.001a | 417,527 (31.4) | 389,958 (21.1) | < 0.001a |
| Telmisartan | 284,014 (21.4) | 281,247 (15.2) | < 0.001a | 284,144 (21.4) | 281,305 (15.2) | < 0.001a |
| Olmesartan | 262,594 (19.8) | 220,217 (11.9) | < 0.001a | 262,736 (19.8) | 220,282 (11.9) | < 0.001a |
| Candesartan | 153,248 (11.5) | 121,081 (6.5) | < 0.001a | 153,317 (11.5) | 121,119 (6.5) | < 0.001a |
| Glimepiride | 142,651 (10.7) | 155,995 (8.4) | < 0.001a | 142,729 (10.8) | 156,042 (8.4) | < 0.001a |
| Carvedilol | 122,643 (9.2) | 134,532 (7.3) | < 0.001a | 122,718 (9.2) | 134,581 (7.3) | < 0.001a |
| Levofloxacin | 121,231 (9.1) | 121,145 (6.5) | < 0.001a | 121,939 (9.1) | 121,238 (6.5) | < 0.001a |
| Celecoxib | 119,071 (9.0) | 108,138 (5.8) | < 0.001a | 119,317 (9.0) | 108,333 (5.9) | < 0.001a |
| Ciprofloxacin | 106,527 (8.0) | 106,308 (5.7) | < 0.001a | 106,656 (8.0) | 106,401 (5.7) | < 0.001a |
| Concurrent use of other drugs affecting skin cancer | ||||||
| Atorvastatin | 420,486 (31.7) | 481,284 (26.0) | < 0.001a | 420,739 (31.7) | 481,455 (26.0) | < 0.001a |
| Aspirin | 392,984 (29.6) | 433,731 (23.4) | < 0.001a | 393,232 (29.6) | 433,896 (23.4) | < 0.001a |
| Methylprednisolone | 377,704 (28.5) | 404,495 (21.8) | < 0.001a | 378,087 (28.5) | 404,742 (21.9) | < 0.001a |
| Prednisolone | 350,951 (26.4) | 346,590 (18.7) | < 0.001a | 351,308 (26.5) | 346,775 (18.7) | < 0.001a |
| Simvastatin | 83,777 (6.3) | 67,847 (3.7) | < 0.001a | 83,823 (6.3) | 67,867 (3.7) | < 0.001a |
Values are presented as mean ± SD or number (%).
NMSC, non-melanoma skin cancer; HCTZ, hydrochlorothiazide.
a
p < 0.05 for HCTZ-users versus non-HCTZ users.
b
Only some of the concurrently administered photosensitizing drugs are listed in order of frequency.